Single-Session Radiotherapy for Cancer-Related Celiac Pain Without a Separate Planning Scan
Tests a faster radiotherapy workflow for celiac pain in adults with advanced cancer.
Plain-language title generated from the registry record
Registry title: Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy in Patients With Cancer-Related Celiac Pain
Key facts
- Where
- Toronto, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or unresectable cancer who have severe upper abdominal and back pain from the celiac plexus and need celiac plexus radiotherapy (SBRT).
- Age
- Older than 18 years.
- Sex
- All sexes can join.
- Disease stage
- Cancer that is metastatic or cannot be removed by surgery, with the celiac plexus involved on imaging (any pancreatic cancer, or another cancer involving the celiac blood vessels or plexus). Severe pain of at least 5 on an 11-point pain scale (BPI average pain). ECOG performance status 3 or better.
- Earlier treatment
- Earlier chemotherapy or biological treatment is allowed. Any active cancer treatment must stop at least 1 week before radiation and restart at least 1 week after it.
Main reasons for not taking part
- Cannot lie flat and still for at least 45 minutes
- ECOG performance status of 4
- Earlier radiotherapy to the upper abdomen overlapping the planned treatment site
- Pregnant or breastfeeding women
- Conditions that raise the risk of radiation side effects, such as inflammatory bowel disease or scleroderma
Read by machine on 9 November 2026.
Where in Canada
- Princess Margaret Cancer CentreToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT07636382
- Record updated
- 30 July 2026
- Original description
This is a prospective, single-arm, pilot feasibility clinical trial designed to evaluate the feasibility and safety of a simulation-free adaptive radiotherapy workflow to enable single-session celiac plexus SBRT planning and delivery. In this trial, the treatment itself is non-investigational (standard-of-care celiac plexus SBRT) but the treatment workflow (simulation-free, using adaptive radiotherapy to compress treatment planning and delivery into a single session) is novel. Investigators hypothesize the successful completion of the simulation-free ART workflow through treatment delivery in the first on-table treatment attempt for at least 80% of patients.Read full original descriptionShow less
A Prospective Pilot Clinical Trial of Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy in Patients With Cancer-Related Celiac Pain
This is a prospective, single-arm, pilot feasibility clinical trial designed to evaluate the feasibility and safety of a simulation-free adaptive radiotherapy workflow to enable single-session celiac plexus SBRT planning and delivery. In this trial, the treatment itself is non-investigational (standard-of-care celiac plexus SBRT) but the treatment workflow (simulation-free, using adaptive radiotherapy to compress treatment planning and delivery into a single session) is novel. Investigators hypothesize the successful completion of the simulation-free ART workflow through treatment delivery in the first on-table treatment attempt for at least 80% of patients.
Inclusion: Subjects must have histologically or cytologically confirmed cancer that is metastatic or unresectable, and considered appropriate per the treating physician to receive celiac plexus SBRT; Age >18 years. Because no data are currently available on the use of celiac axis SBRT in subjects ≤18 years of age, children are excluded from this study; Performance status: ECOG Performance status ≤ 3; Severe retroperitoneal pain syndrome (radiates from the lower back to the upper abdomen, belt- like distribution), intensity of at least 5 on 11-point Brief Pain Inventory (BPI, average pain) scale; Subjects must have anatomical involvement of the celiac plexus on the diagnostic CT, PET/CT, or MRI. This includes: Any pancreatic cancer, any other cancer that on imaging demonstrates either gross involvement of the celiac blood vessels or celiac plexus on imaging OR haziness around the celiac blood vessels that typically implies tumor engulfment; Prior chemotherapy or biological treatment is allowed, but any active oncological treatment should be stopped at least 1 week prior to radiation therapy and renewed at least 1 week following radiation therapy; Subjects must have the ability to understand and the willingness to sign a written informed consent document; Subjects must have a diagnostic CT of the abdomen and pelvis, with or without contrast, acquired < 28 days prior to the study consent.
Exclusion: Previous radiotherapy to the upper abdomen overlapping with the projected site of treatment; Subjects with conditions associated with increased risk of side effects from radiation such as inflammatory bowel disease and scleroderma; In ability to tolerate lying supine and still for at least 45 minutes; Performance status: ECOG Performance status of 4; Pregnant or breastfeeding women are excluded from this study; Women of childbearing potential must have a negative pregnancy test within 14 days of study entry. If pregnancy test is not clinically indicated as determined by treating physician or protocol principal investigator, documentation of this exception is sufficient in lieu of a pregnancy test.